Bank of America Securities analyst Daniel Giraldo maintained a Buy rating on 4D Molecular Therapeutics today and set a price target of $30.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Daniel Giraldo has given his Buy rating due to a combination of factors that highlight the promising potential of 4D Molecular Therapeutics’ 4D-150 treatment. The 60-week follow-up data for 4D-150 in diabetic macular edema (DME) showed results that align with expectations from key opinion leaders, demonstrating sustained improvements in visual acuity and reductions in central subfield thickness. These outcomes suggest a reduced treatment burden, with a significant portion of patients remaining injection-free or requiring minimal rescue injections, which is encouraging for the treatment’s long-term viability.
Furthermore, 4D-150 has maintained a favorable safety profile across various indications, with no signs of intraocular inflammation observed in the study cohort. This aspect is particularly important given the comorbidities often present in DME patients. Additionally, regulatory alignment with both the EMA and FDA on the path forward for DME trials adds to the confidence in the treatment’s potential. The anticipated updates on the 4D-150 trials in wet age-related macular degeneration (wAMD) are expected to further de-risk the program and provide insights into its long-term durability and safety, supporting the Buy rating with a price objective of $30.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $36.00 price target.